Key result
In rats with experimental myocardial infarction, cardiac ACE mRNA expression increased up to 2-fold in the acute phase with captopril or TCV-116 treatment compared to untreated controls (p<0.05).
Why the study?
Does captopril or TCV-116 modify ACE mRNA expression in lung and myocardium after acute myocardial infarction in rats?
Does captopril or TCV-116 modify ACE mRNA expression in lung and myocardium after acute myocardial infarction in rats?
Effect estimate: max 2 fold increase
p-value: p=<0.05
In a rat model of myocardial infarction, cardiac and pulmonary ACE mRNA expression exhibit different temporal patterns, and RAS blockade specifically upregulates cardiac ACE mRNA in the acute phase.
No takes yet. Share an insight, caveat, or question.
Youn et al. (1998) studied Acute myocardial infarction (experimental rat model). Captopril or TCV-116 vs. Placebo (untreated) was evaluated on Cardiac ACE mRNA expression in acute phase after MI (max 2 fold increase, p=<0.05). In rats with experimental myocardial infarction, cardiac ACE mRNA expression increased up to 2-fold in the acute phase with captopril or TCV-116 treatment compared to untreated controls (p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: